Glutaminyl cyclase (QC) activity has been identified as a key effector in distinct biological
processes. Human glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide …

Cancer cells can evade immune surveillance through the expression of inhibitory ligands
that bind their cognate receptors on immune effector cells. Expression of programmed death …

The alpha‐glucosidase inhibitor is a common oral anti‐diabetic drug used for controlling
carbohydrates normally converted into simple sugars and absorbed by the intestines …

Human glutaminyl cyclase (hQC) is an important enzyme for post-translational modification
by converting the N-terminal glutaminyl and glutamyl into pyroglutamate (pGlu) through …

High expression of glutaminyl cyclase (QC) contributes to the initiation of Alzheimer's
disease (AD) by catalyzing the generation of neurotoxic pyroglutamate (pE)-modified β …

The blood-brain barrier (BBB) prevents pathogens and toxins in the bloodstream from
reaching the brain, but also inhibits the delivery of agents intended to treat central nervous …

Pyroglutamate (pE) modification, catalyzed mainly by glutaminyl cyclase (QC), is prevalent
throughout nature and is particularly important in mammals including humans for the …

Human glutaminyl cyclase (hQC) is drawing considerable attention and emerging as a
potential druggable target for Alzheimer's disease (AD) due to its close involvement in the …

Glutaminyl cyclases (QC) catalyze the cyclization of proteins and turn N-terminal glutamine
or glutamic acid into N-terminal pyroglutamate, resulting in protection of proteins from …

A diverse range of N-terminally truncated and modified forms of amyloid-β (Aβ) oligomers
have been discovered in Alzheimer's disease brains, including the pyroglutamate-Aβ …